Catherine Sabatos-Peyton, Ph.D.
Chief Executive Officer

Catherine Sabatos-Peyton, Ph.D., is Larkspur Bioscience’s Chief Executive Officer. Most recently Executive Director, Head of Immune Modulation at the Novartis Institutes for BioMedical Research (NIBR), Catherine spent 7 years building the team focused on biologics and small molecule drug development programs. Previously, while at the biotech CoStim, Catherine led the discovery of the first-in-class anti-TIM-3 antibody, sabatolimab, and then oversaw its advancement to Phase 2/3 studies in acute myeloid leukemia and myelodysplastic syndrome at NIBR. After embarking on autoimmunity research during a Fulbright Fellowship at Oxford, Catherine received her Ph.D. in Immunology from Harvard University.

Krista Goodman, Ph.D.
Chief Scientific Officer

Krista Goodman, Ph.D., is Chief Scientific Officer. She secured both a MS and Ph.D. in Chemistry at Harvard University studying synthetic organic chemistry in the labs of Dave Evans while working on natural products total synthesis. Prior to Larkspur, Krista spent 20 years at GSK, most recently as Global Head and Senior Director of Flexible Medicinal Chemistry, Medicine Design. During her tenure at GSK, Krista served in global leadership roles where her groups were accountable for delivering drug leads and candidates across GSK’s entire portfolio, including oncology and immunology as well as infectious diseases and other areas of focus. She was also accountable for GSK’s chemistry outsourcing strategy and global lab operations. Additionally, while leading a newly formed early discover chemistry group at GSK, Krista and her team prosecuted over fifty different targets across the full spectrum of target classes, therapeutic areas, and small molecule modalities. She also has extensive experience with enzymes and kinases.

Emily Corse, Ph.D.
EVP, Biology & Translation

Emily Corse, Ph.D., is EVP, Biology & Translation. Emily joined Larkspur from Boehringer Ingelheim where she was recruited to build from scratch cancer immunology research in the US, focused on mechanisms that relieve T cell suppression in the tumor microenvironment. Previously, Emily was a Senior Principal Scientist for pRED Cancer Immunotherapy at Roche, where she supported their increased efforts in antibody therapies for cancer immunology. Emily trained in molecular virology and cell biology, then became interested in the elegance of T cell receptor / peptide MHC interactions through an immunology course and pursued that topic as a postdoc with Jim Allison (founder of T cell checkpoint inhibition for oncology and Nobel laureate) at MD Anderson. Before leaving Texas, Emily was an assistant professor of immunology at University of Texas / MD Anderson. She received her Ph.D. in cell biology from Johns Hopkins University School of Medicine.

Leadership Team

Catherine Sabatos-Peyton, Ph.D.

Chief Executive Officer

Krista Goodman, Ph.D.

Chief Scientific Officer

Emily Corse, Ph.D.

EVP, Biology & Translation

Lewis C. Cantley

Lewis C. Cantley, Ph.D., is Professor of Medicine at the Dana Farber Cancer Institute and Professor of Cell Biology at Harvard Medical School.  He obtained a Ph.D. in biophysical chemistry from Cornell University and did postdoctoral training at Harvard University.  Previously the Director of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medical College and New York Presbyterian Hospital, Dr. Cantley has also taught and performed research in biochemistry, physiology and cancer biology at Tufts University School of Medicine and at Beth Israel Deaconess Medical Center and Harvard Medical School.  His laboratory discovered the PI 3-Kinase pathway that plays a critical role in insulin signaling and in cancers.  Dr. Cantley is a member of the National Academy of Sciences and National Academy of Medicine and has received a number of awards for his research, most recently the 2019 Horwitz Prize.  He has founded several companies, including Larkspur Biosciences.

Nathanael Gray

Nathanael Gray, Ph.D., is the Krishnan-Shah Professor of Chemical and Systems Biology at Stanford, Co-Director of Cancer Drug Discovery, Co-Leader of the Cancer Therapeutics Research Program, Member of Chem-H, and Program Leader for Small Molecule Drug Discovery for the Innovative Medicines Accelerator (IMA). His research uses the tools of synthetic chemistry, protein biochemistry, and cancer biology to discover and validate new strategies for addressing anti-cancer targets. Dr. Gray’s research has had broad impact in the areas of kinase inhibitor and degrader design and in circumventing drug resistance. Dr. Gray received his PhD in organic chemistry from the University of California at Berkeley.  Dr. Gray has also been involved in establishing new companies to advance projects from the lab into the commercial sector including Larkspur Biosciences.  His contributions have been recognized through numerous awards including the Paul Marks Prize in 2019.

Vijay K. Kuchroo

Vijay Kuchroo, DVM, Ph.D., is the Samuel L. Wasserstrom Professor of Neurology at Harvard Medical School and Senior Scientist at Brigham and Women’s Hospital.  He is also an Institute member of the Broad Institute, and a participant in a Klarman Cell Observatory project that focuses on T cell differentiation. He is the founding Director of the Evergrande Center for Immunologic Diseases at Harvard Medical School and Brigham and Women’s Hospital. His major research interests include autoimmune diseases, cancer, and neuroimmunology.  Dr. Kuchroo obtained his Ph.D. at the University of Queensland. Dr. Kuchroo has 25 patents and has founded five different biotech companies including Larkspur Biosciences.

Founders

Lewis C. Cantley
Nathanael Gray
Vijay K. Kuchroo

SCIENTIFIC ADVISORS

Lewis C. Cantley, Ph.D. (Chair, SAB)
Antoni Ribas, M.D., Ph.D.
Vijay K. Kuchroo, D.V.M., Ph.D.
Nathanael Gray, Ph.D.
Miriam Merad, M.D., Ph.D.
Jonathan Kagan, Ph.D.
Nir London, Ph.D.

BOARD OF DIRECTORS

BOARD MEMBERS

Amy Schulman, J.D. – Polaris Ventures (Chair)
Nathanael Gray, Ph.D. – Stanford University
Frank Yan, Ph.D. – 3E Bioventures Capital
Sacha Mann, M.Sc., M.B.A. – Takeda Ventures

BOARD OBSERVERS

Alexandra Cantley, Ph.D. – Polaris Ventures
Wei Li, Ph.D., M.B.A. — Creacion Ventures

INVESTORS